Regentis Biomaterials Advances GelrinC Hydrogel Implant Toward Key Commercial Milestones in Knee Cartilage Repair

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure that may offer an alternative to traditional microfracture and complex cell-based therapies. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes.

GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal U.S. Phase III trial that is more than 50% enrolled, positioning Regentis for several upcoming catalysts, including potential European commercialization, completion of the pivotal study, and eventual FDA submission. The company's Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue including inflamed cartilage and bone. GelrinC® is eroded and resorbed in the knee, allowing surrounding cells to regenerate the cartilage in a controlled and synchronous process.

The significance of this announcement lies in the large unmet need for an off-the-shelf regenerative treatment for knee cartilage repair. Currently, microfracture and cell-based therapies like MACI are available but have limitations: microfracture often results in fibrocartilage rather than native hyaline cartilage, while cell-based therapies require two surgeries and are costly. GelrinC® aims to address this gap with a single-step procedure that regenerates near-native cartilage. For a full corporate profile, visit https://ibn.fm/bpPp6.

Forward-looking statements in this press release involve risks and uncertainties, as detailed in the company's SEC filings. Please see the full disclaimer at http://IBN.fm/Disclaimer. The original release is available at https://www.newmediawire.com.